• The Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) is a statutory Committee of Department of Animal Husbandry and Dairying (DAHD), Ministry of Fisheries, Animal Husbandry and Dairying (MoFAH&D) constituted under the Prevention of Cruelty to Animals (PCA) Act, 1960.
• CPCSEA is duty bound to take all such measures as may be necessary to ensure that animals are not subjected to unnecessary pain or suffering before, during or after performance of experiments on them.
INTRODUCTION
• For this purpose, the Committee formulated the Breeding of and Experiments on Animals (Control & Supervision) Rules, 1998 (amended in 2001 & 2006) to regulate the experimentation on animals.
• Under the provisions of the above rules, establishments who are engaged in Bio-medical research, breeding and trading of laboratory animals are required to get themselves registered with CPCSEA.
• There are 19 members in the present CPCSEA wherein Dr. O. P. Chaudhary, Joint Secretary (Animal Welfare) is the Chairman of CPCSEA and Dr. S. K. Dutta, Joint Commissioner (Animal Welfare) is the Member Secretary of CPCSEA.
Need of cpcsea
FUNCTIONS
Institutional Animals Ethics Committee (IAEC)
(a) Every experiment shall be performed by or under the supervision of a person duly qualified.
(b) That experiments are performed with due care and humanity and as far as possible experiments involving operations are performed under the influence of some anaesthetic of sufficient power to prevent the animals from feeling pain;
(c) That animals who, in the course of experiments under the influence of anaesthetics, are so injured that their recovery would involve serious suffering, are ordinarily medically allowed to death while still under influence of anaesthetic;
(d) That experiments on animals are avoided wherever it is possible to do so.
(e) That experiments on larger animals are avoided when it is possible to achieve the same results by experiments on small laboratory animals like guinea-pigs, rabbits, mice, rats etc;
(f) That, as far as possible, experiments are not performed merely for the purpose of acquiring manual skill;
(g) That animals intended for the performance of experiments are properly looked after before, during and after experiments;
(h) That suitable records are maintained with respect to experiments performed on animals
Members of iaec
• A. IAEC members from the establishment (05 members):
• i. One biological scientist
• ii. Two scientists from different biological disciplines
• iii. One veterinarian involved in the care of animal
• iv. One scientist in charge of animal facility of the establishment concerned
• B. Nominees from the CPCSEA:
• i. Main Nominee (01)
• ii. Link Nominee *
• iii. Scientist from outside the Institute (01)
• iv. Socially Aware Nominee (01)
Institutional Biosafety Committee (IBSC)
• Institutional Biosafety Committee (IBSC) is to be constituted in all centers engaged in genetic engineering researc
The document outlines regulatory guidelines for validating traditional medicines through preclinical and clinical studies. It discusses the types of information required in investigational new drug applications (INDs) for botanical drug products, including descriptions of the botanical ingredients, manufacturing and quality controls, pharmacology, toxicity studies, and previous human experience. The level of information required increases from initial clinical trials to expanded clinical trials and approaches for new drug applications (NDAs). Preclinical studies help identify compounds likely to be safe and effective in humans, while clinical trials progress from small initial safety studies to larger efficacy trials.
JSS Medical Research is a full service clinical research organization (CRO) with strong academic affiliations offering a wide range of services internationally. One of our distinguishing attributes is our methodological knowledge and expertise in the design and execution of clinical studies. These include all phases of development such as Phase I, II and III, and post-approval studies. The breadth of our experience enables our clients to collaborate with the same partner throughout the product lifecycle.
Safety monitoring and reporting of adverse events of medical devices national...Vivek Nayak
This document outlines safety monitoring and adverse event reporting for medical devices from national and international perspectives. It defines medical devices and their classification system. Approval processes in India are discussed, along with the Materiovigilance Program of India for post-marketing surveillance. Adverse events must be reported within defined timeframes. International regulatory bodies like the FDA and MHRA also have mandatory reporting requirements. The limitations of current monitoring and reporting are noted.
The document summarizes the requirements and process for submitting a New Drug Application (NDA) to the U.S. FDA for approval to market a new drug product. An NDA must provide extensive documentation about the drug's safety and efficacy established through clinical and non-clinical trials, as well as details on manufacturing processes and quality controls. The application contains multiple technical sections that thoroughly describe the drug's chemistry, manufacturing, pharmacology, clinical data and results. If approved, the NDA permits legal marketing of the new drug in the United States.
This document outlines the standard procedures for clinical trial project management, including standardizing processes, maintaining flexibility, marketing to sponsors, setting up feasibility assessments, developing budgets and contracts, working with regulatory bodies for approval, conducting site initiations, ongoing study coordination, and closing out projects. Key aspects are using templates and checklists, determining feasibility at multiple stages, negotiating budgets, navigating regulatory requirements, and coordinating clinical setup and study conduct. The goal is to save time and reduce risks through standardized yet adaptable processes.
institutional review board and independent ethics committeeMOHAMMAD ASIM
The document discusses the role and responsibilities of institutional review boards (IRBs) in protecting human subjects in clinical research. It provides details on:
- The composition and quorum requirements of IRBs, including the need for diverse expertise and community representation.
- The functions of IRBs, which include reviewing research protocols, approving studies, overseeing informed consent processes, and ensuring ongoing ethical review of approved studies.
- The responsibilities of IRBs in evaluating risks and benefits to research participants, assessing payment amounts and methods, and requiring modifications or halting studies when necessary.
- The necessary components of informed consent forms used in clinical studies, including study details, risks/benefits, confidentiality
The document outlines regulatory guidelines for validating traditional medicines through preclinical and clinical studies. It discusses the types of information required in investigational new drug applications (INDs) for botanical drug products, including descriptions of the botanical ingredients, manufacturing and quality controls, pharmacology, toxicity studies, and previous human experience. The level of information required increases from initial clinical trials to expanded clinical trials and approaches for new drug applications (NDAs). Preclinical studies help identify compounds likely to be safe and effective in humans, while clinical trials progress from small initial safety studies to larger efficacy trials.
JSS Medical Research is a full service clinical research organization (CRO) with strong academic affiliations offering a wide range of services internationally. One of our distinguishing attributes is our methodological knowledge and expertise in the design and execution of clinical studies. These include all phases of development such as Phase I, II and III, and post-approval studies. The breadth of our experience enables our clients to collaborate with the same partner throughout the product lifecycle.
Safety monitoring and reporting of adverse events of medical devices national...Vivek Nayak
This document outlines safety monitoring and adverse event reporting for medical devices from national and international perspectives. It defines medical devices and their classification system. Approval processes in India are discussed, along with the Materiovigilance Program of India for post-marketing surveillance. Adverse events must be reported within defined timeframes. International regulatory bodies like the FDA and MHRA also have mandatory reporting requirements. The limitations of current monitoring and reporting are noted.
The document summarizes the requirements and process for submitting a New Drug Application (NDA) to the U.S. FDA for approval to market a new drug product. An NDA must provide extensive documentation about the drug's safety and efficacy established through clinical and non-clinical trials, as well as details on manufacturing processes and quality controls. The application contains multiple technical sections that thoroughly describe the drug's chemistry, manufacturing, pharmacology, clinical data and results. If approved, the NDA permits legal marketing of the new drug in the United States.
This document outlines the standard procedures for clinical trial project management, including standardizing processes, maintaining flexibility, marketing to sponsors, setting up feasibility assessments, developing budgets and contracts, working with regulatory bodies for approval, conducting site initiations, ongoing study coordination, and closing out projects. Key aspects are using templates and checklists, determining feasibility at multiple stages, negotiating budgets, navigating regulatory requirements, and coordinating clinical setup and study conduct. The goal is to save time and reduce risks through standardized yet adaptable processes.
institutional review board and independent ethics committeeMOHAMMAD ASIM
The document discusses the role and responsibilities of institutional review boards (IRBs) in protecting human subjects in clinical research. It provides details on:
- The composition and quorum requirements of IRBs, including the need for diverse expertise and community representation.
- The functions of IRBs, which include reviewing research protocols, approving studies, overseeing informed consent processes, and ensuring ongoing ethical review of approved studies.
- The responsibilities of IRBs in evaluating risks and benefits to research participants, assessing payment amounts and methods, and requiring modifications or halting studies when necessary.
- The necessary components of informed consent forms used in clinical studies, including study details, risks/benefits, confidentiality
The Therapeutic Goods Administration is the regulatory body for therapeutic goods in Australia.he TGA is responsible for conducting assessment and monitoring activities to ensure that therapeutic goods available in Australia are of an acceptable standard and that access to therapeutic advances is in a timely manner.
The Therapeutic Goods Administration (TGA) is a unit of the Australian Government Department of Health and Ageing that regulates therapeutic goods including medicines and medical devices. The TGA ensures these goods available in Australia meet acceptable standards of quality, safety and efficacy through a risk-based regulatory framework. It has over 700 staff from varied backgrounds including pharmacists, scientists, and medical officers. The TGA operates under the Therapeutic Goods Act of 1989 to provide a national framework for regulating therapeutic goods and maintains the Australian Register of Therapeutic Goods which lists goods approved for supply or export from Australia.
NSF International and its role in Dietary supplements & Nutraceutical industr...SyedArshiya4
This presentation will allow the reader to know about NSF international its history, mission, NSF Mark, role in Dietary supplements and Nutraceutical industries. It also give information on testing, inspection, certification of products.
This presentation is a brief overview of ICH-GCP guidelines. Although ICH-GCP is a very vast topic, still this presentation will cover almost all the points. The reader will be able to discuss about the roles and responsibilities of various personnel in clinical trials.
Schedule Y outlines the requirements and guidelines for permission to import and manufacture new drugs in India and to conduct clinical trials. It aims to regulate clinical research and new drugs. Permission is required from the Central Drugs Standard Control Organization and Drugs Technical Advisory Board for importing or manufacturing new drugs as well as conducting clinical trials. Applications must include chemical, pharmaceutical, pre-clinical, and clinical data. Clinical trials must be approved by licensing authorities and ethics committees and informed consent is required. Sponsors and investigators have responsibilities to patients' rights and safety. Trials progress through Phases I-IV and special studies on populations like geriatrics are addressed along with post-marketing surveillance. Detailed appendices provide guidelines on submitting applications and
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...GOKULAKRISHNAN S
Introduction to ANDA
Regulations applied to ANDA process
Format and content of ANDA
ANDA approval process
Exclusivity
Hatch-Waxman amendments & 180 days exclusivity
Introduction to IMPD
Contents of IMPD
Introduction to IB
Contents of IB
Clinical trials involve testing investigational drugs or treatments on human subjects to determine safety and efficacy. They progress through several phases, beginning with small pre-clinical trials on animals. Phase 1 trials involve 20-50 healthy volunteers to assess pharmacokinetics and safety. Phase 2 trials enroll 50-300 patient volunteers to further evaluate safety and dosage. Phase 3 trials are large randomized controlled trials of 250-1000+ subjects comparing the investigational treatment to standard treatment or placebo. If Phase 3 is successful, the results are submitted to regulatory agencies for approval to market the new drug. Post-marketing Phase 4 trials monitor long-term safety and efficacy.
This document summarizes registration requirements for medicines in three CIS countries - Uzbekistan, Georgia, and Kyrgyzstan. Uzbekistan requires chemical, pharmaceutical, biological, pharmacological, toxicological and clinical documentation be submitted. Georgia requires administrative documents, labeling information approved in the exporting country, and samples. Kyrgyzstan requires an application, power of attorney, GMP certificate, product description and stability data. All three countries require documentation be submitted in their local languages and require stability testing in Zone I conditions.
To import Drug into India, the Site of manufacturing & products are to be registered.We give Services in getting manufacturing licences
ACCREDITED CONSULTANTS PVT.LTD
info@acplgroupindia.co.in
+919310040434
Herbal medicines are popular because of experience and the abundant
availability of plants in India due to its varied climatic zones. India has
around 45,000 species of plants, out of which 15,000–20,000 plants have
proven medicinal value.
Content and format of dossier filling in india sandeep bansal
This document provides an overview of the dossier submission process for drug approval. It discusses the Common Technical Document (CTD) format adopted by the Central Drugs Standard Control Organization of India based on International Conference on Harmonization guidelines. The CTD format organizes the dossier into five modules containing administrative information, quality data, nonclinical studies, clinical studies and references. Compliance with the CTD format and inclusion of all required information is necessary for regulatory approval of new drugs.
Regulation of biosimilars in India is overseen by the Central Drugs Standard Control Organization (CDSCO). Biosimilars must demonstrate similarity to an approved reference biologic in terms of quality, safety and efficacy through comparative clinical and preclinical studies. The guidelines allow for waiving late-stage clinical trials if early studies show high similarity. Three approval protocols exist based on whether the product is indigenous or imported and if the final product contains genetically modified organisms. Biosimilars offer to increase access to biologic treatments in India at a lower cost than originator biologics.
The document discusses Good Laboratory Practice (GLP), which are quality standards for conducting non-clinical safety studies. It was created by the Organization for Economic Co-operation and Development (OECD) to ensure safety studies are conducted properly and results can be relied upon. Poor practices discovered by regulators in the 1970s, like fraudulent data and inaccurate record keeping, led to the formalization of GLP principles. Adhering to GLP helps generate reliable and reproducible safety data that can be shared internationally without non-tariff trade barriers. Key aspects of GLP covered include personnel responsibilities, facility organization requirements, and terms related to studies and quality assurance.
Regulatory medical writing is an integral part of Medical Communications, but is often overlooked. In simple terms, it involves writing of the documents required for the approval of drugs by the regulatory authorities.
https://www.cognibrain.com/regulatory-medical-writing/
The Central Drugs Standard Control Organisation (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. It is responsible for approving new drugs, medical devices, and clinical trials. CDSCO has headquarters in New Delhi and is overseen by the Drug Controller General of India. It has various zonal and sub-zonal offices that perform GMP audits, inspections, and quality control tests. CDSCO uses a multi-step process to approve clinical trials, drugs, cosmetics, and medical devices that involves submitting documents and gaining permission from the DCGI. It also has an online portal called SUGAM to streamline the application process.
The document discusses various drug regulatory authorities around the world including the FDA, TGA, CDSCO, and ICMR. It provides an overview of the roles and responsibilities of these agencies in regulating drugs and pharmaceutical products to ensure public health and safety. Key functions of regulatory authorities that are described include evaluating new drugs, inspecting manufacturing facilities, monitoring adverse events, and establishing product standards.
A brief introduction on medical device , how iit is regulated in india,its marketing authorization,classification, notified devices,import of device and registration process, fnctions of medical device department.
PAREXEL Principal Consultant Angela McGillivary discusses commercial considerations, clinical development, regulatory requirements, submission and post approval strategies in emerging markets
This document provides guidance on product recalls for firms regulated by the FDA. It discusses the different classes of recalls from Class I, which involves serious health risks and requires removing all stocks of the product, to Class III, which is unlikely to cause health issues. The guidance recommends including specific information in submissions to the FDA such as product details, production codes, distribution information, recall strategy, and corrective actions. Firms are responsible for conducting effectiveness checks to ensure recalls are fully carried out.
The document summarizes guidelines from the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) in India. It outlines CPCSEA's objectives to promote humane animal care and avoid unnecessary pain in research. It also describes proper housing, transportation, disease prevention, euthanasia protocols, record keeping, and other standards for animal experimentation facilities. Adhering to CPCSEA guidelines aims to ensure ethical and regulated use of animals for research and testing in India.
This ppt is based on the Animals Act -1960 proposed for the welfare of ANIMALS. It contains the objective and comeetee which were established for the development of animals
The Therapeutic Goods Administration is the regulatory body for therapeutic goods in Australia.he TGA is responsible for conducting assessment and monitoring activities to ensure that therapeutic goods available in Australia are of an acceptable standard and that access to therapeutic advances is in a timely manner.
The Therapeutic Goods Administration (TGA) is a unit of the Australian Government Department of Health and Ageing that regulates therapeutic goods including medicines and medical devices. The TGA ensures these goods available in Australia meet acceptable standards of quality, safety and efficacy through a risk-based regulatory framework. It has over 700 staff from varied backgrounds including pharmacists, scientists, and medical officers. The TGA operates under the Therapeutic Goods Act of 1989 to provide a national framework for regulating therapeutic goods and maintains the Australian Register of Therapeutic Goods which lists goods approved for supply or export from Australia.
NSF International and its role in Dietary supplements & Nutraceutical industr...SyedArshiya4
This presentation will allow the reader to know about NSF international its history, mission, NSF Mark, role in Dietary supplements and Nutraceutical industries. It also give information on testing, inspection, certification of products.
This presentation is a brief overview of ICH-GCP guidelines. Although ICH-GCP is a very vast topic, still this presentation will cover almost all the points. The reader will be able to discuss about the roles and responsibilities of various personnel in clinical trials.
Schedule Y outlines the requirements and guidelines for permission to import and manufacture new drugs in India and to conduct clinical trials. It aims to regulate clinical research and new drugs. Permission is required from the Central Drugs Standard Control Organization and Drugs Technical Advisory Board for importing or manufacturing new drugs as well as conducting clinical trials. Applications must include chemical, pharmaceutical, pre-clinical, and clinical data. Clinical trials must be approved by licensing authorities and ethics committees and informed consent is required. Sponsors and investigators have responsibilities to patients' rights and safety. Trials progress through Phases I-IV and special studies on populations like geriatrics are addressed along with post-marketing surveillance. Detailed appendices provide guidelines on submitting applications and
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...GOKULAKRISHNAN S
Introduction to ANDA
Regulations applied to ANDA process
Format and content of ANDA
ANDA approval process
Exclusivity
Hatch-Waxman amendments & 180 days exclusivity
Introduction to IMPD
Contents of IMPD
Introduction to IB
Contents of IB
Clinical trials involve testing investigational drugs or treatments on human subjects to determine safety and efficacy. They progress through several phases, beginning with small pre-clinical trials on animals. Phase 1 trials involve 20-50 healthy volunteers to assess pharmacokinetics and safety. Phase 2 trials enroll 50-300 patient volunteers to further evaluate safety and dosage. Phase 3 trials are large randomized controlled trials of 250-1000+ subjects comparing the investigational treatment to standard treatment or placebo. If Phase 3 is successful, the results are submitted to regulatory agencies for approval to market the new drug. Post-marketing Phase 4 trials monitor long-term safety and efficacy.
This document summarizes registration requirements for medicines in three CIS countries - Uzbekistan, Georgia, and Kyrgyzstan. Uzbekistan requires chemical, pharmaceutical, biological, pharmacological, toxicological and clinical documentation be submitted. Georgia requires administrative documents, labeling information approved in the exporting country, and samples. Kyrgyzstan requires an application, power of attorney, GMP certificate, product description and stability data. All three countries require documentation be submitted in their local languages and require stability testing in Zone I conditions.
To import Drug into India, the Site of manufacturing & products are to be registered.We give Services in getting manufacturing licences
ACCREDITED CONSULTANTS PVT.LTD
info@acplgroupindia.co.in
+919310040434
Herbal medicines are popular because of experience and the abundant
availability of plants in India due to its varied climatic zones. India has
around 45,000 species of plants, out of which 15,000–20,000 plants have
proven medicinal value.
Content and format of dossier filling in india sandeep bansal
This document provides an overview of the dossier submission process for drug approval. It discusses the Common Technical Document (CTD) format adopted by the Central Drugs Standard Control Organization of India based on International Conference on Harmonization guidelines. The CTD format organizes the dossier into five modules containing administrative information, quality data, nonclinical studies, clinical studies and references. Compliance with the CTD format and inclusion of all required information is necessary for regulatory approval of new drugs.
Regulation of biosimilars in India is overseen by the Central Drugs Standard Control Organization (CDSCO). Biosimilars must demonstrate similarity to an approved reference biologic in terms of quality, safety and efficacy through comparative clinical and preclinical studies. The guidelines allow for waiving late-stage clinical trials if early studies show high similarity. Three approval protocols exist based on whether the product is indigenous or imported and if the final product contains genetically modified organisms. Biosimilars offer to increase access to biologic treatments in India at a lower cost than originator biologics.
The document discusses Good Laboratory Practice (GLP), which are quality standards for conducting non-clinical safety studies. It was created by the Organization for Economic Co-operation and Development (OECD) to ensure safety studies are conducted properly and results can be relied upon. Poor practices discovered by regulators in the 1970s, like fraudulent data and inaccurate record keeping, led to the formalization of GLP principles. Adhering to GLP helps generate reliable and reproducible safety data that can be shared internationally without non-tariff trade barriers. Key aspects of GLP covered include personnel responsibilities, facility organization requirements, and terms related to studies and quality assurance.
Regulatory medical writing is an integral part of Medical Communications, but is often overlooked. In simple terms, it involves writing of the documents required for the approval of drugs by the regulatory authorities.
https://www.cognibrain.com/regulatory-medical-writing/
The Central Drugs Standard Control Organisation (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. It is responsible for approving new drugs, medical devices, and clinical trials. CDSCO has headquarters in New Delhi and is overseen by the Drug Controller General of India. It has various zonal and sub-zonal offices that perform GMP audits, inspections, and quality control tests. CDSCO uses a multi-step process to approve clinical trials, drugs, cosmetics, and medical devices that involves submitting documents and gaining permission from the DCGI. It also has an online portal called SUGAM to streamline the application process.
The document discusses various drug regulatory authorities around the world including the FDA, TGA, CDSCO, and ICMR. It provides an overview of the roles and responsibilities of these agencies in regulating drugs and pharmaceutical products to ensure public health and safety. Key functions of regulatory authorities that are described include evaluating new drugs, inspecting manufacturing facilities, monitoring adverse events, and establishing product standards.
A brief introduction on medical device , how iit is regulated in india,its marketing authorization,classification, notified devices,import of device and registration process, fnctions of medical device department.
PAREXEL Principal Consultant Angela McGillivary discusses commercial considerations, clinical development, regulatory requirements, submission and post approval strategies in emerging markets
This document provides guidance on product recalls for firms regulated by the FDA. It discusses the different classes of recalls from Class I, which involves serious health risks and requires removing all stocks of the product, to Class III, which is unlikely to cause health issues. The guidance recommends including specific information in submissions to the FDA such as product details, production codes, distribution information, recall strategy, and corrective actions. Firms are responsible for conducting effectiveness checks to ensure recalls are fully carried out.
The document summarizes guidelines from the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) in India. It outlines CPCSEA's objectives to promote humane animal care and avoid unnecessary pain in research. It also describes proper housing, transportation, disease prevention, euthanasia protocols, record keeping, and other standards for animal experimentation facilities. Adhering to CPCSEA guidelines aims to ensure ethical and regulated use of animals for research and testing in India.
This ppt is based on the Animals Act -1960 proposed for the welfare of ANIMALS. It contains the objective and comeetee which were established for the development of animals
CPCSEA Guidelines Dr Santosh B Dighe.pdfsantosh Dighe
The document discusses guidelines for animal experimentation in India as established by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). It outlines the roles and responsibilities of CPCSEA and Institutional Animal Ethics Committees (IAEC) in overseeing animal experiments. Key principles include using the lowest phylogenetic species, avoiding pain and suffering, and providing humane care. Guidelines cover areas like animal housing, transportation, disease control, euthanasia methods, and record keeping to ensure proper care and use of animals in experiments.
Animal Testing: Rationale for conducting studies, CPCSEA Guidelines
The use of animals in research is currently an essential component of the drug discovery process.
Animals help us advance our scientific understanding, serve as models to study disease, help us develop and test potential new medicines and therapies.
Animal testing has benefited researchers in understanding how to treat and prevent various conditions such as high blood pressure, diabetes, tuberculosis, polio, muscular dystrophy, and Parkinson's disease.
Education:
Undergraduate teaching to demonstrate effects of various drugs although this has been phased out in most institutes.
Postgraduate teaching to demonstrate the effects of various drugs, to determine the nature of an unknown drug for bioassay, screening methods and to learn skills e.g. administering drugs.
Research:
A larger number and a greater variety of animals are used in pure research than in applied research. This usually involves studies on embryogenesis, developmental biology, behaviour and breeding in Fruit flies, nematodes, mice and rats.
INTRODUCTION
The motto of Prevention of Cruelty to Animals (PCA) Act 1960 as amended in 1982 is to prevent infliction of unnecessary pain or suffering on animals.
The Central Government has constituted a Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), which is duty bound to take all such measures as may be necessary to ensure that animals are not subjected to unnecessary pain or suffering before, during or after the performance of experiments on them.
The goal of these guidelines is to promote the human care of animal used in biomedical and behavioural research and testing.
To avoid/minimize pain and suffering inflicted on experimental animals
Inspection of animal house facilities
It provides guidelines for -
Proper care, housing, breeding, maintenance, handling and use of experimental animals.
Source of experimental animals
Acceptable experimental procedures for anaesthesia and euthanasia.
Registration of establishments conducting animal experimentation or breeding of animals for this purpose.
Selection and assignment of nominees for the Institutional Animal Ethics Committees (IAEC) of the registered establishments.
Approval of Animal House Facilities on the basis of reports of inspections conducted by CPCSEA.
Permission for conducting experiments involving use of animals.
Recommendation for import of animals for use in experiments.
Action against establishments in case of established violation of any legal norm/stipulation.
Conduct of Training Programmes for the Nominees of CPCSEA.
Conduct/Support of Conference/Workshop on Animal Ethics.
To assure quality maintenance and safety of animals used in laboratory studies while conducting biomedical and behavioural research and testing of products.
Quarantine
2. Personal hygiene
3. Environment
4. Physical facility
5. Animal husbandry
6. Animal disposal
7. Documentation
This document provides information on the Standard Operating Procedures (SOP) for Institutional Animal Ethics Committees (IAEC) in India. It outlines the objectives, functions, and composition of IAECs. The key points are:
1) The objective of IAECs is to ensure animal experiments are conducted humanely and with minimum pain or suffering, in accordance with Indian laws and guidelines.
2) The functions of IAECs include reviewing and approving animal research protocols, monitoring studies, and ensuring compliance with regulations.
3) IAECs must have 8 members - 5 from the establishment including a veterinarian, biologist, and facility head, and 3 nominees including a social member from the
The prevention of cruelty to animals act 1960Shaik Rasheed
This presentation give the complete information regarding the The Prevention of Cruelty to Animals Act 1960 including the definitions, composition of IAEC, Breeding and stocking of animals, experiments, offences and penalties.
The document discusses guidelines from the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) in India. It outlines CPCSEA's aim to promote humane care of animals used in research while advancing biological knowledge. Key points include CPCSEA introducing Good Laboratory Practice standards and the 3Rs principles of replacement, reduction and refinement of animal use. Guidelines cover proper housing, care, experimental procedures, record keeping and humane euthanasia to minimize animal suffering.
Animal laboratory care and ethical requirementsHeena Parveen
This document outlines guidelines for animal facilities and experimentation, including standards for housing, care, and treatment of animals. It discusses principles such as minimizing pain and using alternatives to animal testing when possible. The guidelines address requirements for facilities, veterinary care, quarantine of new animals, restraint, surgical areas, environment controls, and record keeping. Proper use of anesthesia, euthanasia procedures, and preventing cruelty are emphasized.
The objective of CCSEA is to ensure that animals are not subjected to unnecessary pain or suffering before, during or after performance of experiments on them. For this purpose, under the delegated powers, the Committee formulated the ‘Breeding of and Experiments on Animals (Control and Supervision) Rules, 1998’ which were amended in 2001 and then in 2006, to regulate the experimentation on animals.
The document outlines guidelines from the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) for laboratory animal facilities. It discusses the goals of providing humane care for research animals and avoiding unnecessary pain. It also covers requirements for veterinary care, quarantine of new animals, disease surveillance, diagnosis and treatment, and control of disease. Institutional Animal Ethics Committees (IAEC) must be formed to monitor animal experiments and ensure ethical practices, with a CPCSEA nominee overseeing compliance.
This document provides information about the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) in India. It discusses that CPCSEA was formed in 1964 under the Prevention of Cruelty to Animals Act to ensure ethical treatment of animals in scientific research. It oversees Institutional Animal Ethics Committees (IAEC) that approve research protocols and inspect animal facilities. The document outlines CPCSEA and IAEC guidelines for housing, care, veterinary support, disease control, anesthesia, euthanasia, record keeping and more to promote humane treatment of animals like mice, rats, and rabbits commonly used in laboratories.
The document discusses animal ethics and care in biomedical research. It covers:
1. The importance of animal models in biomedical research due to their biological similarities to humans.
2. A brief history of animal ethics regulations globally and in India, including the establishment of organizations like CPCSEA to oversee animal experimentation.
3. Guidelines from CPCSEA on proper veterinary care, procurement, quarantine, and disease control for animals used in research.
The document outlines guidelines for the humane treatment of animals used in research experiments as established by the CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals). It discusses requirements for animal housing, care, sanitation, record keeping, transportation, and oversight to minimize pain and suffering. The CPCSEA was established in 1960 to regulate animal experimentation in India and ensure compliance with humane standards.
Prevention of cruelty to animals act,1960P.N.DESHMUKH
Prevention of Cruelty to Animals Act-1960 includes Objectives,
Definitions, CPCSEA - brief overview, Institutional Animal
Ethics Committee, Breeding and Stocking of Animals,
Performance of Experiments, Transfer and Acquisition of
animals for experiment, Records, Power to suspend or
revoke registration, Offences and Penalties.
The document summarizes guidelines from various organizations regarding the use of animals in research and experiments, including CPCSEA, ICMR, and INSA. It outlines standards for veterinary care, housing and facilities, disease prevention and treatment, record keeping, anesthesia, euthanasia, and other procedures to ensure the humane treatment of laboratory animals and that unnecessary pain or suffering is avoided. The guidelines are intended to properly oversee and regulate experimentation on animals.
The document summarizes the Prevention of Cruelty to Animals Act 1960 in India. It outlines the objectives of preventing unnecessary pain/suffering to animals. It defines key terms and outlines the roles and guidelines of Institutional Animal Ethics Committees and the Committee for the Control and Supervision of Experiments on Animals in regulating experiments and care of animals. Infractions are subject to penalties like fines or imprisonment. The overall aim is to ensure humane treatment of animals used in experiments and activities.
The document provides an overview of ICH guidelines and CPCSEA guidelines for quality control and quality assurance in pharmaceutical research. It discusses the ICH guidelines for quality, safety, efficacy, and multidisciplinary topics. It then summarizes the various Q-series ICH guidelines covering stability testing, analytical validation, impurities, pharmacopoeias, biotechnological products, specifications, and more. It concludes with an overview of the objectives, functions and various aspects of animal husbandry and management covered by the CPCSEA guidelines.
The document summarizes the key aspects of the Prevention of Cruelty to Animals Act of 1960 in India. It outlines the objectives of preventing unnecessary pain or suffering to animals. It defines important terms like animals and cruelty. It describes the composition and functions of the Institutional Animal Ethics Committee, which approves animal experimentation protocols. It provides guidelines on breeding, stocking, and experimentation with animals. It discusses the requirements for transferring or acquiring animals, maintaining records, and the powers and penalties around suspending or revoking registrations of establishments that violate the act.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
CPCSEA.pptx
1. CPCSEA GUIDELINES
The Committee for the Purpose of Control and Supervision of Experiments
on Animals
Prepared by
Dhara Mehta
Mparm QA
2. INTRODUCTION
• The Committee for the Purpose of Control and
Supervision of Experiments on Animals
(CPCSEA) is a statutory Committee of
Department of Animal Husbandry and Dairying
(DAHD), Ministry of Fisheries, Animal
Husbandry and Dairying (MoFAH&D)
constituted under the Prevention of Cruelty to
Animals (PCA) Act, 1960.
• CPCSEA is duty bound to take all such measures
as may be necessary to ensure that animals are not
subjected to unnecessary pain or suffering before,
during or after performance of experiments on
them.
2
3. INTRODUCTION
• For this purpose, the Committee
formulated the Breeding of and
Experiments on Animals (Control &
Supervision) Rules, 1998 (amended in
2001 & 2006) to regulate the
experimentation on animals.
• Under the provisions of the above rules,
establishments who are engaged in Bio-
medical research, breeding and trading of
laboratory animals are required to get
themselves registered with CPCSEA.
• There are 19 members in the present
CPCSEA wherein Dr. O. P. Chaudhary,
Joint Secretary (Animal Welfare) is the
Chairman of CPCSEA and Dr. S. K. Dutta,
Joint Commissioner (Animal Welfare) is
the Member Secretary of CPCSEA.
3
5. NEED OF CPCSEA
To ensure that lab animals are well maintained and experiments are carried acc. to norms.
To promote humancare of animals used in research.
To enhance animal well being and quality.
To improve laboratory animal facility.
To prevent cruelty to animals.
5
6. FUNCTIONS
6
Registration of establishments conducting animal experimentation or breeding of animals for this purpose.
Selection and assignment of nominees for the Institutional Animal Ethics Committees of the registered establishments.
Approval of Animal House Facilities on the basis of reports of inspections conducted by CPCSEA.
Permission for conducting experiments involving use of animals.
Action against establishments in case of established violation of any legal norm/stipulation.
Conduct of Training Programmes for the Nominees of CPCSEA.
Conduct / Support of Conference / workshop on Animal Ethics.
8. INSTITUTIONAL ANIMALS ETHICS
COMMITTEE (IAEC)
(a) Every experiment shall be performed by or under the supervision of a person duly qualified.
(b) That experiments are performed with due care and humanity and as far as possible experiments involving
operations are performed under the influence of some anaesthetic of sufficient power to prevent the animals from
feeling pain;
(c) That animals who, in the course of experiments under the influence of anaesthetics, are so injured that their
recovery would involve serious suffering, are ordinarily medically allowed to death while still under influence of
anaesthetic;
(d) That experiments on animals are avoided wherever it is possible to do so.
(e) That experiments on larger animals are avoided when it is possible to achieve the same results by experiments on
small laboratory animals like guinea-pigs, rabbits, mice, rats etc;
(f) That, as far as possible, experiments are not performed merely for the purpose of acquiring manual skill;
(g) That animals intended for the performance of experiments are properly looked after before, during and after
experiments;
8
9. MEMBERS
OF IAEC
• A. IAEC members from the establishment (05
members):
• i. One biological scientist
• ii. Two scientists from different biological
disciplines
• iii. One veterinarian involved in the care of animal
• iv. One scientist in charge of animal facility of the
establishment concerned
• B. Nominees from the CPCSEA:
• i. Main Nominee (01)
• ii. Link Nominee *
• iii. Scientist from outside the Institute (01)
• iv. Socially Aware Nominee (01)
9
10. INSTITUTIONAL BIOSAFETY COMMITTEE
(IBSC)
• Institutional Biosafety Committee (IBSC) is to be constituted in all centers engaged in genetic engineering research and
production activities.
• The biosafety functions and activity include the following:
(a) Registration of Biosafety Committee membership composition with RCGM review committee on genetic manipulation
and submission of report. ISBC will provide half yearly reports on the ongoing projects to RCGM regarding the observance of
the safety guidelines on accidents, risks and on deviations if any.
(b) Review and clearance of project proposals falling under restricted category that meets the requirements under the
guidelines. IBSC would make efforts to issue clearance certificates quickly on receiving the research proposals from
investigators.
(c) Tailoring biosafety program to the level of risk assessment.
(d) Training of personnel on bio safety.
(e) Instituting health monitoring program for laboratory personnel Complete medical check up of personnel working in
projects involving work with potentially dangerous microorganism should be done prior to starting such projects.
(f) 3 Adopting emergency plans.
10
11. GUIDELINES ON THE REGULATION OF
SCIENTIFIC EXPERIMENTS ON ANIMALS
Ministry of Environment & Forests
(Animal Welfare Division)
11
12. AIM & PRINCIPLES
• The aim of these Guidelines is to ensure humane and ethical treatment of
animals, while facilitating legitimate scientific research involving experiments
on animals.
• Ethical principles adopted by CPCSEA for use of animals in scientific
experiments
• Principle 1 “Experiments on animals” (including experiments involving
operations on animals) may be carried out for the purposes of advancement
by new discovery of physiological knowledge; or of knowledge which is
expected to be useful for saving or prolonging human life or alleviating
suffering; or for significant gains in the wellbeing for the people of the 12
13. PRINCIPLE 2
• Animals lowest on the phylogenetic scale (i.e., with the least degree
of sentience), which may give scientifically valid results, should be
used for any experimental procedure. Experiments should be
designed with the minimum number of animals to give statistically
valid results at 95% level of confidence. Alternatives not involving
animal testing should be given due and full consideration and
sound justification provided, if alternative, when available, are not
used
13
14. PRINCIPLE 3
• Proper use of animals in experiments and avoidance or minimization (when
avoidance is not possible) of pain and suffering inflicted on experimental
animals should be an issue of priority for research personnel, and unless the
contrary is scientifically established, investigators should process on the basis
that procedures that cause pain or suffering in human beings will also cause
similar pain or suffering in animals. All scientific procedures adopted with
animals that may cause more than momentary or slight pain and/or suffering
should be performed with appropriate sedation, analgesia or anaesthesia
14
15. PRINCIPLE 4
• Persons engaged in animal experimentation have a moral responsibility for the welfare of the
animals after their use in experiments. Investigators are responsible for the aftercare and/or
rehabilitation of animals after experimentation, and may be permitted to euthanize animals
only in the following situations:
• (a) When the animal is paralyzed and is not able to perform its natural functions; it becomes
incapable of independent locomotion; and/or can no longer perceive the environment in an
intelligible manner.
• (b) During the course of experimental procedure the animal has been left with a severe
recurring pain and the animal exhibits obvious signs of long term extreme pain and suffering.
• (c) In situations where non-termination of the animal experimented upon would be life
threatening to human beings or other animals.
• Costs of aftercare and/or rehabilitation of animals post-experimentation are to be part of
research costs and should be scaled per animal in positive correlation with the level of
sentience of the animals.
15
16. PRINCIPLE 5
• The living conditions of animals should be appropriate for their
species and contribute to their health and comfort. The housing,
feeding, and care of all animals used for biomedical purposes
must be directed by a veterinarian or other scientist in a relevant
discipline who is trained and experienced in the proper care,
handling, and use of the species being maintained or studied. In
all circumstances, veterinary care shall be provided as necessary
16
18. GENERAL
• Good Laboratory Practices (GLP) for
animal facilities is intended to assure
quality maintenance and welfare of
animals used in laboratory studies
while conducting biomedical and
behavioural research and testing of
products.
• The goal of these Guidelines is to
promote the humane care of animals
used in biomedical and behavioural
research and testing with the basic
objective of providing specifications
that will enhance animal well being,
quality in the pursuit of advancement
of biological knowledge that is relevant
to humans and animals.
18
19. • VETERINARY CARE Adequate veterinary care must be provided and is the responsibility of a veterinarian or a
person who has training or experience in laboratory animal sciences and medicine.
• Use of appropriate methods to prevent and control diseases (e.g. vaccination and other prophylaxis, disease
monitoring and surveillance, quarantine and isolation), operative and post-operative care, diagnosis and
treatment of diseases as well as injuries.
• ANIMAL PROCUREMENT All animals (like cattle, buffalo, sheep, goat, pigs, equine etc.) must be acquired
lawfully as per the CPCSEA guidelines.
• Small animals and dogs can be procured from registered breeders.
• Large animals can be procured from farm, farmers or as per guidance of wild life department, as is done in case
of macaques.
• Cats can be bred for their use.
• Rodents can be imported from abroad after necessary licence from Director General of Foreign trade (DGFT) is
obtained for import.
• QUARANTINE, STABILIZATION AND SEPARATION Quarantine is the separation of newly received animals from
those already in the facility until the health and possibly the microbial status of the newly received animals have
been determined.
• An effective quarantine minimizes the chance for introduction of pathogens into an established colony.
• The duration at quarantine in small lab animals is from one week to one month and large animals allowed up to
6 weeks (cat, dog, monkey, etc).
19
20. • Regardless of the duration of quarantine, newly received animals should be given a period for physiologic,
psychologic and nutritional stabilization before their use.
• Physical separation of animals by species is recommended to prevent interspecies disease transmission and
to eliminate anxiety and possible physiological and behavioural changes due to interspecies conflict.
• Such separation is usually accomplished by housing different species in separate rooms; however, cubicles,
laminar-flow units, cages that have filtered air or separate ventilation, and isolators can be used as suitable
alternatives.
• SURVEILLANCE, DIAGNOSIS, TREATMENT AND CONTROL OF DISEASE
• All animals should be observed for signs of illness, injury, or abnormal behaviour by animal house staff. As a
rule, this should occur daily, but more-frequent observations might be warranted, such as during
postoperative recovery or when animals are ill or have a physical deficit. It is imperative that appropriate
methods be in place for disease surveillance and diagnosis
• PERSONAL HYGIENE It is essential that the animal care staff maintain a high standard of personal
cleanliness. Facilities and supplies for meeting this obligation should be provided with appropriate
Personnel Protective Equipment (PPE) e.g. showers, change of uniforms, footwear etc.
• ANIMAL EXPERIMENTATION INVOLVING HAZARDOUS AGENTS
• Institutions should have policies governing experimentation with hazardous agents. Institutional Bio-safety
Committee whose members are knowledgeable about hazardous agents are in place in most of the higher-
level education, research institutes and in many pharmaceutical industries for taking care of safety issues.
This committee shall also examine the proposal on animal experiments involving hazardous agents in
20
21. • MULTIPLE SURGICAL PROCEDURES ON SINGLE ANIMAL Multiple surgical procedures on a single
animal for any testing or experiment are not to be practiced unless specified in a protocol only
approved by the IAEC
• Animals that are used in more than one experiment should be permitted to recover fully from the
first experiment before the subsequent experiment is performed. Certification of attending
veterinarian is however, required before subjecting animal to the second experiment.
• DURATIONS OF EXPERIMENTS No animal should be used for experimentation for more than 3
years unless adequate justification is provided.
• LOCATION OF ANIMAL FACILITIES TO LABORATORIES
• Laboratory animals are very sensitive to their living conditions. It is important that they shall be
housed in an isolated building located as far away from human habitations as possible and not
exposed to dust, smoke, noise, wild rodents, insects and birds. The building, cages and
environment of animal rooms are the major factors, which affect the quality of animals.
• While planning an animal facility the space should be well divided for various activities. The animal
animal rooms should occupy about 50-60% of the total constructed area and the remaining area
should be utilized for services such as stores, washing, office and staff, machine rooms, quarantine
and corridors.
21
22. • FUNCTIONAL AREAS
• Building Materials should be selected to facilitate efficient and hygienic operation of animal
facilities. Durable, moisture-proof, fire-resistant, seamless materials are most desirable for interior
surfaces including vermin and pest resistance.
• Corridor(s) should be wide enough to facilitate the movement of personnel as well as equipments
and should be kept clean.
• Utilities such as water lines, drain pipes, and electrical connections should preferably be accessible
through service panels or shafts in corridors outside the animal rooms.
• Animal Room Doors Doors should not be rust and should be vermin and dust proof. They should
fit properly within their frames and provided with an observation window. Door closures may also
be provided. Rodent barriers can be provided in the doors of the small animal facilities.
• Exterior Windows Windows are not recommended for small animal facilities. However, where
power failures are frequent and backup power is not available, they may be necessary to provide
alternate source of light and ventilation. In primate rooms, windows can be provided to have visual
access to natural environment.
22
23. • Floors Floors should be or either monolithic or epoxy smooth, moisture proof, nonabsorbent, skidproof,
resistant to wear, acid, solvents and adverse effects of detergents/ disinfectants. They should be capable of
supporting racks, equipment, and stored items without becoming gouged, cracked, or pitted, with
minimum number of joints.
• Drains Floor drains are not essential in all rooms used exclusively for housing rodents. Floor in such rooms
can be maintained satisfactorily by wet vacuuming or mopping with appropriate disinfectants or cleaning
compounds. Where floor drains are used, the floors should be sloped and drain taps kept filled with water
or corrosion free mesh. To prevent high humidity, drainage must be adequate to allow rapid removal of
water and drying of surfaces. At the inlet and outlets of the drains should be fitted with wire mesh guard to
prevent wild rodent entry
• Walls & Ceilings Walls should be free of cracks, unsealed utility penetrations, or imperfect junctions with
doors, ceilings, floors and corners. Surface materials should be capable of withstanding scrubbing with
detergents, disinfectants and the impact of water under high pressure. Materials used for construction of
roof should cater needs of local climatic condition to provide comfort to the animals. IX.
• Separate storage areas should be designed for feed, bedding, cages and materials not in use. Refrigerated
storage, separated from other cold storage, is essential for storage of dead animals and animal tissue waste
• Facilities For Sanitizing Equipment And Supplies An area for sanitizing cages and ancillary equipment is
essential with adequate water supply
• Experimental Area All experimental procedures in small animals should be carried out in a separate area
away from the place where animals are housed. Aseptic surgery for large animals should include separate
functional areas for surgical support, like a preparation area, the operating theatre room or rooms, and an
area for post operative care and for treatment of animals. 23
24. • Walls & Ceilings Walls should be free of cracks, unsealed utility penetrations, or
imperfect junctions with doors, ceilings, floors and corners. Surface materials
should be capable of withstanding scrubbing with detergents, disinfectants and
the impact of water under high pressure. Materials used for construction of roof
should cater needs of local climatic condition to provide comfort to the animals.
• Storage Areas Separate storage areas should be designed for feed, bedding,
cages and materials not in use. Refrigerated storage, separated from other cold
storage, is essential for storage of dead animals and animal tissue waste.
• Facilities For Sanitizing Equipment And Supplies An area for sanitizing cages and
ancillary equipment is essential with adequate water supply
• Experimental Area All experimental procedures in small animals should be
carried out in a separate area away from the place where animals are housed.
Aseptic surgery for large animals should include separate functional areas for
surgical support, like a preparation area, the operating theatre room or rooms,
and an area for post operative care and for treatment of animals.
24
25. ENVIRONMENT
• Temperature And Humidity
Control
Temperature - 18 to 29°C
Humidity - 30% to 70%
• Ventilation Heating, ventilation,
and air-conditioning systems should
be designed with 12-15 air cycles
per hour
• Power And Lighting Fluorescent
lights are efficient and less than 400
lux is preferable for rodent facilities.
• Noise Control Preferably less than
85 dB is desirable for rodents and
non human primates.
25
26. • FOOD
Animals should be fed with palatable, non-contaminated, and nutritionally adequate food daily
unless the experimental protocol requires otherwise. Feeders should allow easy access, while
avoiding contamination by urine and faeces
• BEDDING
Bedding should be absorbent, free from toxic chemicals or other substances that cause irritation,
injure animals or personnel, and of a type not readily eaten by animals. Bedding should be used in
in amounts sufficient to keep animals dry between cage changes without coming into contact
with watering tubes.
• WATER
Animals should have continuous access to fresh, potable, uncontaminated drinking water,
according to their requirements. Periodic monitoring of microbial contamination in water is
necessary.
• WASTE DISPOSAL
• PEST CONTROL
26
27. RECORD KEEPING
Ø Animal House plans, which includes typical floor plan, all fixtures etc.
Ø Animal House staff record - both technical and non - technical
Ø Health record of staff and animals
Ø All SOPs relevant to experiments, care, breeding and management of animals
Ø Breeding, stock, purchase and sales records
Ø Minutes of institutional Animals Ethics Committee Meetings
Ø Records of experiments conducted with the number of animals used (copy of Form D)
Ø Mortality, Post-mortem Record, wherever required.
Ø Clinical record of sick animals.
Ø Training record of staff involved in animal activities
Ø Water, feed and bedding materials analysis report
Ø Health monitoring Records.
Ø Rehabilitation Records, wherever required.
27
28. ANAESTHESIA
• Unless contrary to the achievement of the
results of study, sedatives, analgesics and
anaesthetics should be used to control pain
or distress under experiment.
• Before using actual anaesthetics the
animals are prepared for anaesthesia by
overnight fasting and using pre-
anaesthetics, which block parasympathetic
stimulation of cardio-pulmonary system
and reduce salivary secretion.
• Atropine is most commonly used anti-
cholinergic agent.
28
29. EUTHANASIA
• Euthanasia should be resorted to events
where an animal is required to be sacrificed
to reduce suffering or to limit spread of
infections or for termination of an
experiment or for other ethical reasons.
• Death, without causing anxiety, pain or
distress with minimum time lag phase.
Minimum physiological and psychological
disturbances.
• Compatibility with the purpose of study
and minimum emotional effect on the
operator.
• Location should be separate from animal
rooms and free from environmental
contaminants.
• Tranquilizers have to be administered to
larger species such as monkeys, dogs and
cats before a procedure of euthanasia.
29